Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Inipharm logo — Inipharm is a biopharmaceutical company focused on discoveri...

Inipharm

Inipharm is a biopharmaceutical company focused on discovering and developing therapies for severe liver diseases.

Founded 2018 7 employees Series A Total: $35.00M Biotechnology, Health Care +1

General Information

Company Name Inipharm
Founded Year 2018
Employees 7
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with Inipharm. To contact Inipharm, visit inipharm.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Inipharm

Inipharm is a biopharmaceutical company that focuses on discovering and developing therapies for severe liver diseases. Founded in 2018, the company operates within the industries of Biotechnology, Health Care, and Pharmaceuticals. In November 11, 2020, Inipharm secured a significant $35.00M Series A investment from notable investors including 5AM Ventures, Frazier Healthcare Partners, Wu Capital, and Jubilant Biosys. This substantial investment underlines the potential and promise of Inipharm's mission to address severe liver diseases, making it a compelling opportunity for venture capitalists looking to invest in the biopharmaceutical sector.

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Series A $35.00M 4
5AM Ventures Frazier Healthcare Partners Wu Capital
5AM Ventures, Frazier Healthcare Partners +2
01 Nov 2020

Inipharm Alternatives & Competitors

View All Alternatives
Inipharm vs
CymaBay Therapeutics
CymaBay Therapeutics United States

Dedicated to improving the lives of patients with liver diseases

Acquired
32 employees
Biopharma, Biotechnology
Inipharm vs
Structure Therapeutics
Structure Therapeutics United States

Developing accessible oral small molecule therapies for the treatment of chronic diseases including...

IPO
219 employees
Biotechnology, Health Care
Inipharm vs
Caribou Biosciences
Caribou Biosciences United States

Clinical-stage biopharmaceutical company developing transformative therapies to treat devastating hu...

IPO
128 employees
Biotechnology, Health Care
Also compare with: Inipharm vs VectivBio VectivBio View all alternatives

FAQ About Inipharm

Inipharm is a biopharmaceutical company focused on discovering and developing therapies for severe liver diseases.
Inipharm was founded in 2018.
Inipharm operates in Biotechnology, Health Care and Pharmaceutical.
Inipharm has approximately 7 employees.
Inipharm has completed 1 funding round, raising a total of $35.00M. The latest funding stage is Series A.
Top alternatives and competitors to Inipharm include CymaBay Therapeutics, Structure Therapeutics, Caribou Biosciences, Lanthio Pharma, Intercept Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Inipharm and CymaBay Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Inipharm, https://bouncewatch.com/company/inipharm, updated 9 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes